Skip to content

Intra-Cellular Therapies, Inc.

CIK 0001567514

← back to feed
Revenue (TTM)
$607.8M
+13.6% YoY FY Mar 2025
Net Income (TTM)
−$82.05M
+35.9% YoY FY Mar 2025
EPS Diluted (TTM)
−$0.82
+36.0% YoY FY Mar 2025
Gross Margin
—
FY Mar 2025
Operating Margin
-19.3%
FY Mar 2025
Net Margin
-13.5%
FY Mar 2025
Free Cash Flow (TTM)
−$225.39M
FY Mar 2025
Cash
$306.95M
FY Mar 2025
Total Debt
—
FY Mar 2025
Shares Outstanding
106.52M sh
FY Mar 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings